HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

False Treatment Claims Still A COVID-19 Symptom: FTC Files Complaint Against California Firm

Executive Summary

FTC files complaint alleging Precision Patient Outcomes marketed a supplement as a treatment to mitigate the effects of COVID-19 after agency let the firm know it considered the claims false advertising.

You may also be interested in...



US FTC Section 13(b) Revamp Gains Traction With Senate ‘Fix’ In The Works

There is strong support for a bipartisan fix to discourage marketplace fraud and anticompetitive practices and enable consumer redress under the FTC Act. But Congress is distracted and deeply divided with different ideas about how extensive the FTC’s authorities should be under Section 13(b) of the FTC Act.

More Access To US Consumers Means More False Claims For COVID-19 Than Other Health Dangers

While types of unsupported claims were no different than those advertisers made when US was hit it by other widespread health emergencies, digital capabilities made advertisers’ response to COVID-19 different, says Rich Cleland, FTC Consumer Protection Bureau attorney.

FTC Will Ask Congress To Sharpen Monetary Relief Authority Dulled By Supreme Court Ruling

Justice Breyer suggests FTC ask Congress to strengthen its enforcement rules. It is “free to ask Congress to grant it further remedial authority,” according to court opinion stating a rule the FTC has wielded for forty years to impose financial penalties doesn’t grant it authority to obtain equitable monetary relief.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

RS153133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel